CSI Market
Sign In | Register

Intellipharmaceutics International Inc (IPCIF) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access IPCIF Annual Income Statement →
Income statement data covering Intellipharmaceutics International Inc–May 31 2023 offers a view into how Nov 30 2022's operating results have moved alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Nov 30 2022)
Q4 2023 		0 (Aug 31 2023) 0 (May 31 2023)
Revenues
Total Revenue0.07
Costs & Expenses
Cost of Goods and Services Sold0.00
Gross Profit0.07
Selling, Administration, Marketing0.56
Depreciation & Amortization0.21
Research and Development Expense2.15
Restructuring, Accretion & Impairment Charges0.00
Other Operating Expense / -Income-0.04
Total operating costs including COS2.92
Operating income / -loss-2.85
Interest Expense0.29
Interest Expense, Borrowings0.00
Net Interest (-)Expense / Income-0.29
Foreign Currency Transaction Gain (Loss), before Tax-0.21
Other loss / -income-0.04
Total costs & expenses2.95
Income & Taxes
Income / -loss before income taxes-2.89
Income taxes expenses / -benefit0.01
Income after income taxes-2.89
Net income / -loss of other equity0.00
Income / -loss from continuing operations-2.89
Net income / -loss-2.89
Income / -loss to shareholder-0.88
EBIT-2.60
EBITD-2.44
EBITDA-2.44
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Intellipharmaceutics International Inc income statement history.

Sign In Create Free Account

About IPCIF Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.